Managing Nausea and Vomiting During Ketamine Therapy

Managing nausea and vomiting during ketamine therapy starts with recognizing that nausea, not dissociation, is usually the side effect most likely to make a patient stop treatment early. Nausea affects roughly one in four to one in three patients receiving subanesthetic ketamine for depression, chronic pain, or other conditions, and the rate varies by dose and route of administration. It comes from four overlapping mechanisms: direct stimulation of the brain's chemoreceptor trigger zone, a sensory mismatch similar to motion sickness, gastrointestinal irritation with oral or sublingual dosing, and mild activation of the sympathetic nervous system. Nausea is largely predictable and preventable. Identifying at-risk patients before the first infusion, giving prophylactic antiemetics such as ondansetron, and adjusting the infusion rate or route can reduce nausea significantly. This guide covers the mechanisms, risk factors, and antiemetic protocols clinicians use to keep patients comfortable and in treatment.

Why Ketamine Causes Nausea

Ketamine and its metabolite norketamine directly stimulate the chemoreceptor trigger zone (CTZ), a region in the brainstem that sits outside the blood-brain barrier and monitors the blood for circulating toxins. When the CTZ detects ketamine, it signals the vomiting center in the medulla, and this pathway operates even with intravenous dosing that bypasses the gut entirely.

A second driver is vestibular mismatch. Ketamine's dissociative effects create a disconnect between visual, proprioceptive, and inner-ear signals, similar to the mechanism behind motion sickness. Patients with a history of car sickness or vestibular sensitivity tend to report more nausea for this reason. Oral and sublingual formulations add a third pathway: direct irritation of the gastric mucosa and ketamine's bitter taste can trigger the gag reflex and activate vagal nerve signals to the brainstem. Finally, ketamine's mild sympathomimetic effects, including catecholamine release, can lower the threshold for nausea through shared autonomic pathways with the emetic reflex.

Who Is Most Likely to Have Nausea

Some patients are far more likely to experience ketamine-induced nausea than others, which lets clinicians target prophylaxis instead of medicating everyone by default. The strongest predictors include:

• A history of motion sickness, the single strongest predictor of nausea with ketamine
• Female sex, which carries roughly 1.5 to 2 times the nausea risk seen in men, mirroring patterns in postoperative nausea and vomiting
• A prior history of postoperative nausea and vomiting with general anesthesia
• High baseline anxiety, especially in treatment-naive patients, which can produce anticipatory nausea before the infusion starts
• Younger age
• Higher doses, faster infusion rates, and oral or sublingual dosing, which carries more nausea risk than standard IV dosing because of added gastrointestinal irritation
• Eating within two hours of treatment

First-Line Prevention: Ondansetron

Ondansetron (brand name Zofran) is a serotonin 5-HT3 receptor antagonist that blocks the receptors most responsible for triggering nausea signals from the CTZ and the gut, and it is the best-supported antiemetic for ketamine-induced nausea. The standard dose is 4 mg orally or intravenously, given 20 to 30 minutes before the ketamine infusion for maximal receptor blockade. Clinical experience and retrospective data suggest prophylactic ondansetron reduces nausea incidence by roughly 40 to 60 percent in patients receiving standard-dose IV ketamine. Common side effects are headache and constipation, and it still helps as a rescue medication when given after nausea starts, though it works better as prevention.

Second-Line and Adjunct Options

Patients with breakthrough nausea, or contraindications to 5-HT3 antagonists, have several alternatives. Promethazine (12.5 to 25 mg orally or rectally) targets vestibular-mediated nausea but adds to ketamine's sedative effects. Metoclopramide (10 mg orally or IV) helps when delayed gastric emptying contributes to symptoms, though it should be avoided in patients with Parkinson disease. A granisetron transdermal patch, applied 24 to 48 hours ahead of treatment, offers sustained coverage for refractory nausea. A single 4 to 8 mg IV dose of dexamethasone can be added to ondansetron for difficult cases. Scopolamine patches, applied behind the ear three to four hours before treatment, work well for patients with a strong motion sickness history but cause dry mouth and blurred vision. Because several of these agents interact with other sedatives or psychiatric medications, review the full drug interaction profile before adding a second antiemetic.

Non-Drug Strategies That Help

A preprocedure fast of two to four hours for solids and one to two hours for liquids reduces gastric distension and nausea risk, though complete fasting isn't necessary and can itself cause lightheadedness in some patients. A cool, quiet, dimly lit room with the patient reclined and still, a cool damp cloth on the forehead, and calming music through headphones all reduce the sensory input that can trigger nausea. Ginger, taken as a 250 mg capsule or chew 30 to 60 minutes before treatment, has established antiemetic effects in chemotherapy and postoperative settings and is a reasonable low-risk addition, though it hasn't been studied specifically for ketamine. Acupressure wristbands that stimulate the P6 point on the inner wrist have research support for chemotherapy and postoperative nausea. According to the National Cancer Institute, antiemetic strategies used for chemotherapy-related nausea target overlapping serotonin and dopamine pathways in the CTZ, which is part of why measures developed for oncology patients carry over reasonably well to ketamine-induced nausea.

Route Matters: IV, Oral/Sublingual, and Intranasal

With IV ketamine, nausea is mostly CTZ and vestibular in origin, and infusion rate is a powerful lever. Slowing a standard infusion from 40 minutes to 50 or 60 minutes often reduces nausea with little effect on outcomes. Oral and sublingual ketamine add gastrointestinal irritation to the mix. Patients should hold sublingual doses under the tongue for 10 to 15 minutes and spit out the remainder rather than swallowing, since swallowed ketamine contributes disproportionately to GI-related nausea. Flavoring from a compounding pharmacy can also mask the bitter taste that triggers gagging. Esketamine (brand name Spravato) is an FDA-approved intranasal form of ketamine's S-enantiomer used for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires supervised administration. According to the FDA's approval announcement for Spravato, nausea occurred in roughly 25 to 30 percent of patients in clinical trials, a rate comparable to IV ketamine.

Building a Clinic Protocol

At intake, screen for motion sickness history, prior PONV, female sex, anxiety, and medications affecting GI motility, then route high-risk patients (two or more factors) toward prophylactic ondansetron, a slower first infusion, and scopolamine when motion sickness is prominent. Low-risk patients can often skip routine prophylaxis and use ondansetron as rescue only. Documenting nausea severity at each visit, alongside standard monitoring already in place for ketamine sessions, makes it easier to adjust the antiemetic plan for the next treatment rather than repeating a regimen that didn't work.